Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Aleve formulation

This article was originally published in The Tan Sheet

Executive Summary

Liquid Gels target active consumers ages 25 to 49 who suffer from back and joint pain, according to Bayer HealthCare. Available now in food, drug and mass retail outlets, Liquid Gels combine the all-day pain relieving power of Aleve (naproxen sodium) with "liquid-fast" speed and convenient dosing, according to the company. "Just two Aleve Liquid Gels can provide this all-day relief, where it would take four or even eight pills with other brands," the firm claims. The gels are sold in 20-, 40-, 80- and 160-count sizes, with suggested retail prices starting at $5.49...

You may also be interested in...



In Brief

Perrigo launches Aleve generic

P&G’s 'Naturally Derived' Ingredient Claims On Herbal Essences, Pantene Draw Class Action

According to plaintiffs in California federal court, P&G’s claims on Herbal Essences and Pantene shampoo and conditioner products about high proportions of natural-origin or naturally derived ingredients are false and/or misleading, and ISO 16128 certification does not cure the deception.

Funding Doubles Women’s Health Firm Perelel’s Support, Boosts Odyssey Elixir Energy Visibility

Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel